Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | CRHBP | P24387 | 1/20 | 0.61 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.50 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.50 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | MTOR | P42345 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6258232 | 0.94 | CRHBP (0.56) | MAPTCYP1A2CYP2D6CRHBPCRHR2 | |
| SCHEMBL14024999 | 0.90 | MAPT (0.56) | MAPTCYP1A2CYP2D6CRHBPCRHR2 | |
| SCHEMBL3634900 | 0.89 | HRH4 (0.61) | MAPTCYP1A2CYP2D6CRHBPCRHR2 | |
| SCHEMBL908493 | 0.87 | MAPT (0.71) | MAPTCYP1A2CYP2D6CRHBPCRHR2 | |
| SCHEMBL3637243 | 0.87 | CYP1A2 (0.49) | MAPTCYP1A2CYP2D6CRHBPCRHR2 | |
| SCHEMBL15938813 | 0.84 | CYP2C19 (0.56) | MAPTCYP1A2CYP2D6CRHBPCRHR2 | |
| SCHEMBL3293436 | 0.83 | CRHBP (0.77) | MAPTCYP1A2CYP2D6CRHBPCRHR2 | |
| SCHEMBL18284900 | 0.83 | CYP1A2 (0.46) | MAPTCYP1A2CYP2D6CRHBPCRHR2 | |
| SCHEMBL3353780 | 0.81 | NPSR1 (0.69) | MAPTPOLBHTTPIK3CAPIK3CB | |
| SCHEMBL13779832 | 0.80 | HRH4 (0.57) | MAPTCYP1A2CRHBPCRHR2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101796046-A | Pyrimidine derivatives 934 | ASTRAZENECA AB | 2010-08-04 | — | — | CN | disclosed |
| US-7718653-B2 | Pyrimidine derivatives for inhibiting Eph receptors | ASTRAZENECA AB (SE) | 2010-05-18 | — | — | US | disclosed |
| EP-2183242-A2 | PYRIMIDINE DERIVATIVES 934 | AstraZeneca AB (SE) | 2010-05-12 | — | — | EP | disclosed |
| EP-2150545-A1 | N' - (PHENYL) -N- (MORPHOLIN-4-YL-PYRIDIN-2-YL) -PYRIMIDINE-2, 4-DIAMINE DERIVATIVES AS EPHB4 KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE CONDITIONS | AstraZeneca AB (SE) | 2010-02-10 | — | — | EP | disclosed |
| US-20090036440-A1 | NOVEL PYRIMIDINE DERIVATIVES - 816 | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | US | disclosed |
| US-20090036440-A1 | NOVEL PYRIMIDINE DERIVATIVES - 816 | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | US | disclosed |
| US-20090036440-A1 | NOVEL PYRIMIDINE DERIVATIVES - 816 | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | US | disclosed |
| US-20090023719-A1 | PYRIMIDINE DERIVATIVES 934 | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
| WO-2009010789-A2 | PYRIMIDINE DERIVATIVES 934 | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | WO | disclosed |
| WO-2008132505-A1 | N' - (PHENYL) -N- (MORPHOLIN-4-YL-PYRIDIN-2-YL) -PYRIMIDINE-2, 4-DIAMINE DERIVATIVES AS EPHB4 KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE CONDITIONS | ASTRAZENECA AB (SE) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008132505-A1 | N' - (PHENYL) -N- (MORPHOLIN-4-YL-PYRIDIN-2-YL) -PYRIMIDINE-2, 4-DIAMINE DERIVATIVES AS EPHB4 KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE CONDITIONS | ASTRAZENECA AB (SE) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036440-A1 | NOVEL PYRIMIDINE DERIVATIVES - 816 | EPHB4, EPHB6, EPHB1 | MAPT 3461/4885CYP1A2 1950/4885CYP2D6 509/4885 |
| US-20090023719-A1 | PYRIMIDINE DERIVATIVES 934 | EPHB4, EPHA2, EPHB1 | MAPT 4133/4885CYP1A2 346/4885CYP2D6 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.